Premium
Mitomycin C and Aminoglutethimide in the Treatment of Metastatic Prostatic Cancer: a Phase II Study
Author(s) -
DIK P.,
BLOM J. H. M.,
SCHRÖDER F. H.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/bju.1992.70.5.542
Subject(s) - aminoglutethimide , medicine , toxicity , mitomycin c , urology , phases of clinical research , cancer , gastroenterology , chemotherapy , surgery , breast cancer , aromatase
Summary In a phase II study, 24 patients with metastatic prostatic cancer were treated with mitomycin C 15 mg/m 2 i.v. every 6 weeks, combined with aminoglutethimide 250 mg twice a day. A low dose of 37.5 mg cortisone acetate was supplied daily to compensate for adrenal cortical suppression. A partial reponse was demonstrated in 4 of 24 evaluable patients with bidimensionally measurable metastases. Stable disease occurred in 8 patients over a period of more than 6 months. Within the maximum cumulative dose limit of 2 mg/kg body weight mitomycin C, toxicity was observed in 21 cases, including 2 deaths due to treatment toxicity. The poor response rate and high toxicity suggest that the addition of aminoglutethimide does not enhance the effect of mitomycin C in these patients.